Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.

Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon

Sanofi (EPA: SAN) said on Monday its candidate COVID-19 vaccine that it developed with Britain's GlaxoSmithKline (LON: GSK) showed promising results in early-stage clinical trials, paving the way to move ahead with a late-stage trial. Sanofi said: “The Phase II interim results showed 95% to 100% seroconversion following a second injection in all age groups […] The post Sanofi releases vaccine study results, Dr Gottlieb comments on mask-wearing appeared first on Invezz.

Sanofi releases vaccine study results, Dr Gottlieb comments on mask-wearing

GlaxoSmithKline

Yet competition with Pfizer and Moderna could still be stiff.

Sanofi Executives Say Covid Vaccine Could Be 'Universal Booster'

GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market reaction despite posting positive mid-stage trial results for their COVID-19 vaccine.

GSK and Sanofi look to catch up in vaccine race with booster doses

GlaxoSmithKline and Sanofi plan to join vaccine race with booster doses

A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.

Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response' As Firms Aim For Approval Later This Year

Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join the fight against the pandemic. The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study

News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor

GlaxoSmithKline and Sanofi report strong results in trials of Covid vaccine

GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion following a second injection in all age groups, with acceptable tolerability and with no safety concerns.

GlaxoSmithKline, Sanofi post positive mid-stage trial results for COVID-19 vaccine

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune response s across all adult age groups in Phase 2 trial

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

One of the world's most closely watched coronavirus vaccine programs reported positive data on Monday from a mid-stage clinical trial, paving the way for the start of a massive human trial that could allow the shot to be authorized before the end of this year. Sanofi and GlaxoSmithKline, two of the largest vaccine-makers in the world, said in a press release that their experimental coronavirus vaccine led to strong immune responses across all ages in a study that enrolled 722 volunteers. It's a much-needed piece of positive news for the two industry leaders, which saw their vaccine effort delayed by disappointing data announced in December, and have fallen far behind rivals like Moderna, Pfizer-BioNTech, and Johnson & Johnson.

Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shot

The two drugmakers say it might be most useful as a booster shot.

Sanofi and Glaxo Are Back With a Covid-19 Vaccine

You might want to add this international blue-chip stock to your portfolio.

Is Sanofi a Good Buy in 2021?

AstraZeneca

The companies have a promising RSV candidate.

Could AstraZeneca and Sanofi Win Big in RSV?

PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

Sanofi (SNY) CEO Paul Hudson on Q1 2021 Results - Earnings Call Transcript

Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings: Overall sales increased by 2.4%, attributed mainly to Dupixent's success, with vaccines also contributing with a 5.3% rise in sales to €915 million.

Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran

AbbVie

British American Tobacco

Canadian Natural Resources

Chevron

Enbridge

Coca-Cola

Novartis

Realty Income Corp

Pembina Pipeline

AT&T

TC Energy

Unilever

Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These International “Dividend Aristocrats” have raised dividends at least five straight years (Canadian), 10 years (European Union), or 25 years (U.S. companies).

Update: 91 'Top Dividend Stocks On Earth' For May

Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.

Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View

The French pharma giant, which has fallen behind in the Covid-19 vaccine race, said results from a Phase 2 study into its candidate with GlaxoSmithKline are expected next month.

Sanofi Beats Earnings Estimates and Reveals Covid-19 Vaccine Progress

Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and cold treatments dented by lockdowns.

Eczema treatment and vaccines lift Sanofi first quarter results

Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER

Moderna

As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The agreement marks the third different company Sanofi has paired with to manufacture a COVID-19 vaccine since their effort to develop a shot faced significant setbacks.

Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine

The shots could be geared towards children, new variants or boosters.

Moderna Receives Vaccine-Making Boost As Sanofi Signs Up To Manufacture 200 Million Doses For Americans

French drug maker Sanofi S.A. has agreed to make Moderna Inc.'s COVID-19 vaccine at its site in Ridgefield, New Jersey, and will fill and finish up to 200 million doses starting in September.

News for Sanofi Stock (SNY)